Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: CRP identifies homeostatic immune oscillations in cancer patients: a potential treatment targeting tool?
Author: Coventry, B.
Ashdown, M.
Quinn, M.
Markovic, S.
Yatomi-Clarke, S.
Robinson, A.
Citation: Journal of Translational Medicine, 2009; 7(1):102
Publisher: BioMed Central Ltd.
Issue Date: 2009
ISSN: 1479-5876
Statement of
Brendon J Coventry, Martin L Ashdown, Michael A Quinn, Svetomir N Markovic, Steven L Yatomi-Clarke and Andrew P Robinson
Abstract: The search for a suitable biomarker which indicates immune system responses in cancer patients has been long and arduous, but a widely known biomarker has emerged as a potential candidate for this purpose. C-Reactive Protein (CRP) is an acute-phase plasma protein that can be used as a marker for activation of the immune system. The short plasma half-life and relatively robust and reliable response to inflammation, make CRP an ideal candidate marker for inflammation. The high- sensitivity test for CRP, termed Low-Reactive Protein (LRP, L-CRP or hs-CRP), measures very low levels of CRP more accurately, and is even more reliable than standard CRP for this purpose. Usually, static sampling of CRP has been used for clinical studies and these can predict disease presence or recurrence, notably for a number of cancers. We have used frequent serial L-CRP measurements across three clinical laboratories in two countries and for different advanced cancers, and have demonstrated similar, repeatable observations of a cyclical variation in CRP levels in these patients. We hypothesise that these L-CRP oscillations are part of a homeostatic immune response to advanced malignancy and have some preliminary data linking the timing of therapy to treatment success. This article reviews CRP, shows some of our data and advances the reasoning for the hypothesis that explains the CRP cycles in terms of homeostatic immune regulatory cycles. This knowledge might also open the way for improved timing of treatment(s) for improved clinical efficacy.
Keywords: Humans; Neoplasms; Inflammation; C-Reactive Protein; Periodicity; Homeostasis; Biomarkers, Tumor
Rights: © 2009 Coventry et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
RMID: 0020094276
DOI: 10.1186/1479-5876-7-102
Appears in Collections:Surgery publications

Files in This Item:
File Description SizeFormat 
hdl_57400.pdfPublished version2.22 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.